Last reviewed · How we verify
Clinimix E 2.75/5 Sulfite Free W/ Elect In Dextrose 5% W/ Calcium In Plastic Container (POTASSIUM PHOSPHATE, DIBASIC)
At a glance
| Generic name | POTASSIUM PHOSPHATE, DIBASIC |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
| First approval | 1975 |
Approved indications
Common side effects
- pulmonary embolism due to pulmonary vascular precipitates
- hyperkalemia
- hyperphosphatemia
- hypocalcemia
- hypovolemia
- osmotic diuresis
- hypotension
- arrhythmia
- heart block
- cardiac arrest
- bradycardia
- chest pain
Key clinical trials
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
- Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation (PHASE2)
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- Benefits of Alcoholic Hangover Medicine (NA)
- Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT) (PHASE4)
- Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes (EARLY_PHASE1)
- Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: